Torpezil 5/Torpezil 10

Dementia of the Alzheimer's type. Mild, moderate & severe Alzheimer's disease.

Mild to moderate Alzheimer's disease Initially 5 mg once daily in the evening, just prior to retiring. Max: 10 mg daily. Dose of 10 mg should not be administered until patients have been on a daily dose of 5 mg for 4-6 wk. Moderate to severe Alzheimer's disease Initially 5 mg once daily in the evening, just prior to retiring. Dose of 10 mg should not be administered until patients have been on a daily dose of 5 mg for 4-6 wk.

May be taken with or without food: Do not crush/cut in ½.

Hypersensitivity to donezepil HCl or piperidine derivatives. Patients w/ GI or urinary tract obstruction. Not recommended in patients recovering from bladder or GI surgery. Pregnancy.

May exaggerate succinylcholine-type muscle relaxation during anesth. May have vagotonic effects on heart rate (eg, bradycardia) which may be particularly important to patients w/ sick sinus syndrome or other supraventricular cardiac conduction conditions eg, SA or AV block. Reports of syncope & seizures; consider possibility of heart block or long sinusal pauses when investigating. Diarrhea, nausea, & vomiting which appear more frequently w/ 10-mg daily dose than 5-mg daily dose. Closely monitor patients for symptoms of active or occult GI bleeding, especially those at increased risk of developing ulcers eg, those w/ history of ulcer disease or receiving concurrent NSAIDs. May cause bladder outflow obstruction. Potential to cause generalized convulsions; to exacerbate or induce extrapyramidal symptoms. Caution in patients w/ history of asthma or obstructive pulmonary disease. Avoid concomitant use w/ other inhibitors of acetylcholinesterase, agonists or antagonists of cholinergic system. No data in patients w/ severe hepatic impairment. Caution in nursing mothers. Not recommended in childn.

Common cold; anorexia; hallucinations, agitation, aggressive behavior; syncope, dizziness, insomnia; diarrhea, vomiting, nausea, abdominal disturbance; rash, pruritus; muscle cramps; urinary incontinence, headache, fatigue, pain; minor increase in serum conc of muscle creatinine kinase.

Inhibition of metabolism w/ ketoconazole & quinidine (strong inhibitors of CYP450 3A & 2D6). Increased AUC w/ CYP2D6 inhibitors. Increased mean conc (AUC_0-24 & C_max) w/ ketoconazole. Increased rate of elimination w/ CYP3A inducers (eg, phenytoin, carbamazepine, dexamethasone, rifampin & phenobarb).

Neurodegenerative Disease Drugs

N06DA02 - donepezil ; Belongs to the class of anticholinesterases. Used in the management of dementia.

Rx